City of Hope to participate in NCI-MATCH clinical trial

April 5, 2019 | by City of Hope

NCI Match | City of Hope From left to right: Patricia Aoun, M.D., M.P.H., Carrie Louie, Ph.D., Raju Pillai, M.D., Michelle Afkhami, M.D., Javier Arias-Stella, M.D., Milhan Telatar, Ph.D.
 
City of Hope’s Clinical Molecular Diagnostic Laboratory (CMDL) is participating as a CLIA-Certified/Accredited laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial. The trial is co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group.
 
“It’s a privilege to join an elite group of academic and commercial laboratories and participate in this groundbreaking precision medicine effort,” said Milhan Telatar, Ph.D., director of the CMDL in the Department of Pathology.   
 
The NCI-MATCH (EAY131) phase 2 precision medicine clinical trial (NCT02465060) is evaluating the effectiveness of treatment that is directed by genomic profiling in patients with solid tumors, lymphomas or myelomas that have progressed following standard treatments expected to prolong survival, or for rare cancer types for which there is no standard treatment.
 
Tumor gene testing by a designated lab is the only pathway for patients to enroll in the trial. “We are so excited that our NCI-designated cancer Center, City of Hope, is now offering its next generation sequencing-based test, HopeSeq Solid Tumor,” said Michelle Afkhami, M.D., medical director of CMDL.
 
CMDL is one of several labs referring patients to the trial. Through this partnership, CMDL is identifying patients at City of Hope with specific genomic findings who may be eligible to participate in the trial, based on their HopeSeq genomic profiling results. Upon identification of a qualifying genetic alteration abnormality (such as a mutation, amplification or translocation), CMDL will notify the treating oncologist that the patient may be potentially eligible for NCI-MATCH and provide an official referral letter or associated documentation. Using this notification/referral provided by CMDL, the treating physician and their patient may choose to pursue enrollment in the screening step of the study to see if they meet eligibility requirements for the trial.
 
Oncologists at other NCI-MATCH participating sites may contact CMDL and request genomic testing for their patients to determine whether they may potentially be candidates for the trial. Physicians may contact CMDL at [email protected] or call 844-313 5227.
 
To learn more about NCI-MATCH, including the lab referral process and clinical trial sites across the country, visit http://www.ecog-acrin.org/nci-match-eay131.
 
The Clinical Molecular Diagnostic Laboratory at City of Hope’s Department of Pathology is known for its diagnostic excellence. With state-of-the-art laboratory equipment, the team uses superior investigative skills to accurately and rapidly identify the genomic profile of tumors.
 
****

Sign up to receive the latest updates on City of Hope news, medical breakthroughs, and prevention tips straight to your email inbox!

Back To Top

Search Blogs